Rebamipide for Gastric Protection
Overview and Indications
Rebamipide is an effective mucoprotective agent indicated for gastric ulcer, chronic gastritis with hyperacidity, erosive gastritis, and prevention of NSAID-induced gastrointestinal mucosal injury. 1, 2
Approved Indications
- Gastric ulcer treatment 1
- Chronic gastritis with hyperacidity in acute stage 1
- Erosive gastritis 1
- Prevention of gastrointestinal mucosal damage during NSAID therapy 1
- Helicobacter pylori eradication support 1
Dosing Regimen
The standard dose is 100 mg three times daily for 8-12 weeks. 3, 4, 5
Treatment Duration by Indication
- NSAID-induced gastropathy prevention: 100 mg three times daily for 12 weeks 3, 4
- Gastric ulcer healing: 100 mg three times daily for 8 weeks 5
- Chronic gastritis: 100 mg three times daily, duration based on endoscopic response 5
Administration Instructions
- Take orally three times per day 3, 4
- No specific food timing requirements documented in available evidence
- Continue for full prescribed duration even if symptoms improve 5
Mechanism of Action
Rebamipide provides gastroprotection through multiple pathways:
- Stimulates prostaglandin synthesis 5, 6
- Enhances mucus glycoprotein production 5, 2
- Scavenges free oxygen radicals 3, 2
- Inhibits inflammatory cytokines 5
- Prevents neutrophil activation 5
- Maintains gastric mucosal blood flow 6
Efficacy Evidence
NSAID-Induced Injury Prevention
Rebamipide is as effective as misoprostol in preventing NSAID-induced gastric ulcers but with significantly better tolerability. 3, 4
- Gastric ulcer occurrence rate: 20.3% with rebamipide vs 21.9% with misoprostol (p=0.6497) 3
- Withdrawal rate: 10.3% with rebamipide vs 18.6% with misoprostol (p=0.0103) 3
- Gastrointestinal symptom severity: Significantly lower with rebamipide than misoprostol (p=0.0002) 3
- Antacid consumption: Significantly lower with rebamipide (p=0.0258) 3
Comparison with PPIs
Rebamipide demonstrates comparable efficacy to proton pump inhibitors in preventing NSAID-induced mucosal breaks. 7
- Risk ratio 1.00 (95% CI 0.51-1.95, P=1.00) when compared to standard PPIs 7
- May serve as alternative in patients with contraindications to long-term PPI use 7, 2
Gastric Ulcer Healing
Rebamipide is particularly effective for NSAID-induced gastric ulcers, with complete healing in most patients. 5
- Significant improvement in symptom scores (5.9 vs 0.6, p<0.001) 5
- Favorable improvement in gastric inflammation scores in NSAID users (2.38 vs 1.75, p=0.011) 5
- Maintains gastric mucosal blood flow, preventing NSAID-induced reduction 6
Contraindications
No specific contraindications are documented in the available evidence. 1, 3, 4, 5
Side Effects and Safety Profile
Rebamipide demonstrates excellent safety with minimal adverse effects. 3, 5, 2
Adverse Event Profile
- Very low incidence of adverse effects 5
- Well tolerated across all patient groups 5
- Significantly fewer gastrointestinal side effects compared to misoprostol 3
- No diarrhea or abdominal cramping (unlike misoprostol which causes 20% withdrawal rate) 3
Alternative Therapies
First-Line Alternatives (Per Guidelines)
For NSAID-induced gastropathy prevention, PPIs are the guideline-recommended preferred agents. 8
Proton Pump Inhibitors
- Standard once-daily dosing of lansoprazole, omeprazole, or other PPIs 8
- Superior to H2-receptor antagonists and misoprostol for NSAID ulcer prevention 8
- Proven to reduce upper GI bleeding risk in aspirin users 8
Misoprostol
- FDA-approved for NSAID ulcer prevention 8
- Effective but limited by diarrhea and abdominal cramping (20% discontinuation rate) 8
- Rarely used in clinical practice due to poor tolerability 8
H2-Receptor Antagonists
- Standard doses do NOT prevent most NSAID-related gastric ulcers 8
- Double-dose may have some efficacy but inferior to PPIs 8
- Not recommended as first-line therapy 8
Sucralfate
- NOT effective for prevention or treatment of NSAID-related gastric ulcers 8
- Use not recommended due to availability of superior alternatives 8
Risk-Stratified Approach (Per Guidelines)
For patients NOT on aspirin:
- Without previous GI event: NSAID alone (if age <65 years) 9
- With previous GI event: COX-2 inhibitor OR NSAID + PPI 9
For patients ON aspirin:
- Without previous GI event: COX-2 inhibitor OR NSAID + PPI 9
- With previous GI event: NSAID + PPI OR COX-2 inhibitor + PPI 9
Clinical Positioning of Rebamipide
Rebamipide represents a viable alternative to PPIs for NSAID gastroprotection, particularly in patients with PPI contraindications or intolerance. 7, 2
Advantages Over Standard Therapy
- Comparable efficacy to PPIs without long-term acid suppression concerns 7, 2
- Superior tolerability compared to misoprostol 3
- Maintains gastric mucosal blood flow 6
- Multi-mechanistic gastroprotection beyond acid suppression 2
Clinical Scenarios Favoring Rebamipide
- Patients requiring long-term NSAID therapy with PPI contraindications 7, 2
- Patients with poor PPI response or intolerance 2
- Combination with H. pylori eradication therapy 1, 5
- Patients with concerns about long-term PPI adverse effects 7, 2
Common Pitfalls and Caveats
- Do not assume rebamipide is available in all countries: Widely used in Southeast Asia and Russia but not FDA-approved in the United States 2
- Do not discontinue therapy prematurely: Full 8-12 week course needed for optimal ulcer healing 3, 4, 5
- Do not use as monotherapy for H. pylori eradication: Should be adjunctive to standard eradication regimens 1
- Recognize guideline preference for PPIs: Despite rebamipide's efficacy, current guidelines prioritize PPIs as first-line therapy 8